3Oya Uygur-Bayramicli,Resat Dabak,Ekrem Orbay,Can Dolapclo■lu,Mehmet Sargin,Gamze Kilico■lu,Yüksel Güleryüzlü,Alpaslan Mayada■li.Type 2 diabetes mellitus and CA 19-9 levels[J].World Journal of Gastroenterology,2007,13(40):5357-5359. 被引量：64
4Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I ( IGF-I ), IGF binding proteins, their biologic interactions, and colorectal Cancer [ J ] . J Natl Cancer lnst, 2002, 94 ( 13 ) : 972-980.
5Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma [ J ]. Onco- gene ,2010,29 ( 36 ) :4989-5005.
6Soung YH, Chung J. Curcumin inhibition of the functional interaction between integrin c6134 and the epidermal growth factor receptor [ J]. Mol Cancer The,2011 ,10(5) :883-891.
7Kushida M, Kamendulis LM, Peat TJ, et al. Dose-related induction of hepatic preneoplastic lesions by diethylnitrosamine in C57BL/6 mice [ J 1. Toxicol Patho1,2011,39 (5) :776-786.
8Sharma S, Gao P, Steele VE. Quantitative morphometry of respiratory tract epithelial cells as a tool for testing chemopreventive agent efficacy [ J ]. Anticancer Res ,2010,30 (3) :737-742.
9Coulouarn C, Factor VM, Conner EA, et al. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer [ J ]. Carcinogenesis ,2011,32 (10) : 143414-3440.
10Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies [ J ]. Therap Adv C.astroentero1,2010,3 ( 1 ) :55-66.
